Feature | Heart Valve Technology | April 15, 2016

Aquilion One CT Family Aids TAVR Planning

Toshiba showcases how CT Is a cost effective solution to helping make TAVR procedures more efficient for patients at ACC

TAVR runoff image

A 3-D CT reconstruction of a TAVR run-off image to assess the femoral access route using Toshiba's Aquillion One and Vital Images advanced visualization technologies. 

April 15, 2016 — Accurate and precise anatomical information is crucial to successful transcatheter aortic valve replacement (TAVR) procedures, and Toshiba America Medical Systems said its Aquilion One family of CT systems can deliver the visualization he technologies needed during planning. The system gives clinicians the image detail and system flexibility required for planning and performing these procedures. Toshiba showcased these abilities at this year’s American College of Cardiology (ACC) annual meeting April 2-4. 

The Aquilion One family features the industry’s thinnest slices of 0.5 mm and comes in three configurations, including the Aquilion One 320, Aquilion One 640 and Aquilion One Vision Edition. To improve workflow and make TAVR planning more efficient, the systems feature wide detector volumetric cardiac capabilities and Toshiba’s Adaptive Diagnostics technology like the variable helical pitch (vHP), which automatically changes from an ECG-gated to a non-ECG-gated acquisition during a single helical scan, reducing IV contrast and radiation dose. Vital’s CT TAVR planning application can also be utilized to visualize and measure vascular anatomy for the evaluation, treatment and follow up of aortic vascular disorders. 

All Aquilion One family systems are XR-29 compliant and come standard with Toshiba’s complete suite of dose reduction technologies, including AIDR 3D Enhanced.  

“Toshiba’s Aquilion One family plays a critical role in TAVR planning, with its unique ability to acquire anatomical and functional data in a single heartbeat,” said Dominic Smith, senior director, CT, PET/CT, and MR business units, Toshiba. “The Aquilion One Family offers clinical and operational solutions that make work flow and contribute to many cost efficiencies by making pre-procedure TAVR planning more efficient.”

For more information: www.medical.toshiba.com. 

 

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init